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Chemotherapy-induced oral mucositis is
associated with detrimental bacterial
dysbiosis
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Joseph A. Burleson4, Andrew L. Salner5, Peter K. Schauer5, Pujan Joshi6, Evan Fox1, Dong-Guk Shin6,
George M. Weinstock2, Linda D. Strausbaugh3, Anna Dongari-Bagtzoglou1, Douglas E. Peterson1 and
Patricia I. Diaz1*
Abstract
Background: Gastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant
yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes
the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the
response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial
communities disrupting the homeostatic balance between resident microorganisms and the adjacent mucosa
and if such alterations are associated with mucositis. To gain knowledge on the pathophysiology of oral
mucositis, 49 subjects receiving 5-fluorouracil (5-FU) or doxorubicin-based chemotherapy were evaluated
longitudinally during one cycle, assessing clinical outcomes, bacterial and fungal oral microbiome changes,
and epithelial transcriptome responses. As a control for microbiome stability, 30 non-cancer subjects were
longitudinally assessed. Through complementary in vitro assays, we also evaluated the antibacterial potential
of 5-FU on oral microorganisms and the interaction of commensals with oral epithelial tissues.
Results: Oral mucositis severity was associated with 5-FU, increased salivary flow, and higher oral granulocyte
counts. The oral bacteriome was disrupted during chemotherapy and while antibiotic and acid inhibitor intake
contributed to these changes, bacteriome disruptions were also correlated with antineoplastics and independently and
strongly associated with oral mucositis severity. Mucositis-associated bacteriome shifts included depletion of common
health-associated commensals from the genera Streptococcus, Actinomyces, Gemella, Granulicatella, and Veillonella and
enrichment of Gram-negative bacteria such as Fusobacterium nucleatum and Prevotella oris. Shifts could not be explained
by a direct antibacterial effect of 5-FU, but rather resembled the inflammation-associated dysbiotic shifts seen in other
oral conditions. Epithelial transcriptional responses during chemotherapy included upregulation of genes involved in
innate immunity and apoptosis. Using a multilayer epithelial construct, we show mucositis-associated dysbiotic shifts may
contribute to aggravate mucosal damage since the mucositis-depleted Streptococcus salivarius was tolerated as a
commensal, while the mucositis-enriched F. nucleatum displayed pro-inflammatory and pro-apoptotic capacity.
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Conclusions: Altogether, our work reveals that chemotherapy-induced oral mucositis is associated with bacterial
dysbiosis and demonstrates the potential for dysbiotic shifts to aggravate antineoplastic-induced epithelial injury. These
findings suggest that control of oral bacterial dysbiosis could represent a novel preventive approach to ameliorate oral
mucositis.
Keywords: Microbiome, Cancer, Chemotherapy, Oral mucositis, Mucosal-microbial crosstalk
Background
One of the most frequent complications of chemotherapy is
oral mucositis, reported to affect about 75% of patients re-
ceiving high-dose conditioning chemotherapy prior to
hematopoietic cell transplantation and 20 to 60% of individ-
uals treated for solid tumors [1, 2]. Lesions present as
erythema and ulceration of the non-keratinized mucosa. Al-
though the condition is self-limiting, it can impact the deliv-
ery of optimal cancer treatment, since it is associated with
clinically significant pain, compromised nutrition, prolonged
hospitalization, bloodstream infections and antineoplastic
dose reductions [3, 4]. Different approaches to prevent or
treat oral mucositis have been largely ineffective as there is
insufficient knowledge on its pathophysiology [5].
Oral mucositis primarily results from the cytotoxic
effects of chemotherapeutics on the rapidly dividing oral
epithelium, with other areas along the gastrointestinal tract
also commonly affected. Antineoplastics exert their cyto-
toxic effects by a variety of mechanisms leading to im-
paired DNA replication and repair, cell-cycle arrest, DNA
damage, and cell death [6, 7]. However, the specific down-
stream cellular events mediating oral epithelial damage
remain poorly characterized. It has been proposed that oral
microbiome communities, which live in constant cross-talk
with the adjacent mucosal tissues, could contribute to the
development of mucositis [8, 9]. Evidence from animal
models of intestinal mucositis suggests it is plausible that
epithelial-microbiome cross-talk along the gastrointestinal
track modulates susceptibility to mucositis, with resident
microbial commensals shown to be necessary for
irinotecan-dependent intestinal mucosal injury [10]. Also,
mice deficient in the innate immunity activator Toll-like
receptor 2 show increased susceptibility to methotrexate-
induced intestinal mucositis, an indication that microbial
signaling could modify the severity of the response [11].
It is not completely clear how chemotherapy alters the
oral environment. Various studies in humans using
microbiological techniques with limited power of detec-
tion indicate the oral microbiota changes during cancer
treatment [12, 13]. However, there is a paucity of longi-
tudinal, well-controlled studies that use highly sensitive
high throughput sequencing to characterize the oral
microbiome during chemotherapy. Disruption of micro-
biome communities, allowing growth of pathobionts,
could negatively impact the ability of mucosal tissues to
remain intact during an antineoplastic challenge. The
plausibility of this hypothesis was demonstrated in an
animal model of intestinal mucositis, in which the anti-
neoplastic cisplatin induced significant changes in the
intestinal microbiome, but restoration of the gut micro-
biota through fecal-pellet gavage promoted healing of
cisplatin-induced mucositis [14]. It is possible that simi-
lar events take place in the oral cavity, where chemo-
therapy could induce microbiome disruptions that affect
the susceptibility of oral tissues to mucositis.
Alterations in the oral microbiome during chemotherapy
could result from impairment of the different constituents
involved in maintaining these communities in a commensal
state. It has been suggested that chemotherapy compro-
mises the flow of saliva, one of the most important defense
mechanisms in the oral cavity [15, 16]. Chemotherapy-asso-
ciated myelosuppression could also compromise the avail-
ability of oral neutrophils, resulting in a more permissive
environment for detrimental oral microorganisms. Other
chemotherapy-associated treatments such as antibiotics
could also affect the oral microbiome. In addition, antineo-
plastics have been shown to have antimicrobial activity and
could potentially contribute to microbiome changes during
chemotherapy [17, 18].
Here, we present results of a comprehensive longitu-
dinal evaluation of subjects undergoing 5-fluorouracil
(5-FU) or doxorubicin-based chemotherapy, characteriz-
ing changes in the bacterial and fungal oral microbiome,
salivary flow rate (SFR), and oral granulocyte availability
during one treatment cycle and in relation to the devel-
opment of oral mucositis. As a control for microbiome
stability, non-cancer subjects were also longitudinally
sampled. We found that oral mucositis correlated with
the dose of 5-FU, docetaxel, and cisplatin, increased sal-
ivary flow, and greater oral granulocyte presence.
Chemotherapy disrupted the oral bacteriome with these
shifts showing a strong correlation with oral mucositis
severity. Shifts were not specific to mucositis lesions but
rather affected the oral cavity as a whole. Microbiome
shifts associated with mucositis were independent from
the effect of antibiotics and acid inhibitors. Although
shifts correlated with antineoplastic doses, and 5-FU
showed potential to modify directly the microbiome,
mucositis-associated shifts were unlikely the result of a
selective antibacterial action of 5-FU, as commensals
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depleted during mucositis were resistant to physiologically
relevant drug concentrations and Fusobacterium nuclea-
tum, a species enriched during mucositis, was sensitive to
5-FU. Bacteria with a longitudinal change in abundance
that negatively correlated with mucositis severity included
species of Streptococcus, Actinomyces, Gemella, Granulica-
tella, and Veillonella, all common in oral health, while
more severe mucositis correlated with enrichment of
Gram-negatives previously associated with other oral in-
flammatory conditions [19]. These results are consistent
with mucositis-associated dysbiosis as a result of alterations
in nutritional resources due to inflammation, echoing other
oral conditions in which inflammatory products promote
pathobiont growth, which in turn alters host responses
[20]. To better understand mucosal responses during
chemotherapy, we longitudinally characterized oral epithe-
lial transcriptome changes in a subset of subjects, finding
genes involved in the innate immune response and apop-
tosis, among others, to be upregulated. The potential for a
dysbiotic microbiome to modify mucosal responses was
evaluated in a 3D oral mucosa multilayered construct. In
this model, we show that Streptococcus salivarius, a poten-
tial symbiont depleted during mucositis, is tolerated by the
oral mucosa. In contrast, Fusobacterium nucleatum subsp.
vincentii, associated with more severe mucositis, has pro-
inflammatory and pro-apoptotic effects on oral epithelial
cells. To our knowledge, this study provides the first
comprehensive characterization of oral mucositis patho-
physiology in humans demonstrating bacterial dysbiosis is
associated with lesion severity, with such bacteriome
changes showing clear potential to contribute to mucositis
by promoting further epithelial damage.
Results
Oral mucositis is associated with 5-FU exposure
To better understand the pathophysiology of oral mucosi-
tis we followed 49 subjects during one cycle of 5-FU- or
doxorubicin-based chemotherapy (Additional file 1: Figure
S1 and Additional file 2: Tables S1 and S2) and recorded
the incidence and severity of oral mucositis. Fig. 1a shows
Fig. 1 Incidence and clinical presentation of oral mucositis during chemotherapy and correlation with antineoplastics. a Intraoral images of a patient
affected by oral mucositis. b Mucositis incidence according to the WHO scale, which evaluates in a categorical scale of 0 to 4 objective signs and patient-
reported symptoms, and to the OMAS scale, which is based solely on objective signs of erythema and ulceration. OMAS scores reported here could range
from 0 to 45 and represent the aggregated scores from nine intra-oral sites evaluated. c, d The clinical progression of mucositis in mucositis-positive
subjects (n = 32 for the WHO scale and n = 37 for OMAS). Graphs show individual data points with median and range. ** indicates a p value < 0.01 and ***
indicates a p value < 0.001 when comparing each time point to baseline via Wilcoxon matched-pairs signed rank tests. e Incidence of mucositis in subjects
taking 5-FU and those on doxorubicin. * indicates a p value of < 0.05 when comparing incidence via chi-square. f Correlations between chemotherapeutic
total drug doses and mucositis severity. Data represent Spearman correlation coefficients with p values in parenthesis. Colored cells show correlations
significant after adjustment for multiple comparisons via the FDR method. Only drugs given to at least 15% of subjects were included in the analysis
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a typical oral mucositis clinical presentation with ery-
thema and ulceration affecting mostly the non-keratinized
mucosa. As seen in Fig. 1b, mucositis occurred in 65 to
76% of subjects as measured via the WHO and OMAS
scales, respectively, with mucositis severity peaking at V3
(Fig. 1c, d). Mucositis incidence was higher in subjects on
the 5-FU-based regimen in comparison to those taking
doxorubicin (Fig. 1e, WHO p = 0.016 and OMAS p =
0.019), and a moderate but highly significant positive cor-
relation was seen between the dose of 5-FU and mucositis
severity (Fig. 1f). The doses of docetaxel and cisplatin,
which were commonly given in combination with 5-FU
(Additional file 2: Table S2), also positively correlated with
more severe mucositis; while other drugs given with 5-FU
such as carboplatin, oxaliplatin and the chemoprotectant
leucovorin showed no correlation or a negative correlation
with mucositis severity (Fig. 1f).
Oral mucositis is associated with increased salivary flow
and greater oral neutrophil presence
A longitudinal analysis was next conducted to better
understand if disruptions in two important oral homeo-
static mechanisms, saliva and neutrophil surveillance, oc-
curred during chemotherapy and were associated with
mucositis. Changes in these variables were evaluated by
comparing values at each visit to baseline and by modelling
the change over four visits with linear or quadratic polyno-
mial contrasts. In contrast to previous reports [15], we
found that SFR increased during chemotherapy (Fig. 2b, p
= 0.06 at V3; p = 0.028 at V4; and p = 0.002 for linear
change). Increased SFR correlated with more severe muco-
sitis, as shown by significant correlations between the
linear increase in SFR during the cycle and the change in
mucositis symptoms modelled either quadratically (Fig. 2c,
p = 0.001) or linearly (Additional file 2: Table S3, p =
0.003). These findings suggested mucositis was not associ-
ated with decreased saliva, but instead, mucosal inflamma-
tion and ulceration occurred concomitant with and/or
were followed by increased SFR.
Since neutrophil surveillance could affect oral homeo-
stasis by controlling the growth of oral commensals,
which could in turn affect mucosal health, we evaluated
the effect of chemotherapy on blood and oral neutrophil
counts. As expected due to antineoplastic cytotoxicity,
blood neutrophil counts in the cancer group decreased
at V3 in comparison to baseline levels (p = 0.00009);
however, at V4 neutrophil counts rebounded (Fig. 2e).
Decreased blood neutrophils in the middle of the cycle
(positive quadratic change) correlated with a linear in-
crease in mucositis severity (Fig. 2f, p = 0.001 and Add-
itional file 2: Table S3, p = 0.001). Oral neutrophils enter
the oral cavity through the thin junctional epithelium at
the gingiva/tooth interface and via transmucosal migra-
tion [21]. Although chemotherapy decreased blood
neutrophils, oral granulocytes did not follow a similar pat-
tern, only decreasing slightly at V2 (Fig. 2h, p = 0.015). A
linear change in oral granulocytes positively correlated
with a linear change in mucositis severity (Fig. 2i, p =
0.007). Taken together, these findings indicate that despite
decreased blood neutrophils as a consequence of chemo-
therapy, these cells were still being recruited into the oral
tissues, with mucositis lesions promoting increased efflux
of granulocytes into the oral space.
Additional file 2: Table S3 shows other demographic
and clinical characteristics that correlated with the longi-
tudinal clinical progression of oral mucositis. The nega-
tive quadratic change in mucositis severity (low, high,
low) was associated with 5-FU (p = 0.004) but also with
number of prosthetic teeth (p = 0.003) and wearing a re-
movable oral prosthesis (p = 0.002). A linear change in
mucositis severity, indicating subjects with more severe
mucositis late in the cycle (delayed healing), positively
correlated with smoking (p = 0.007), steroid intake (p =
0.002), and cisplatin dose (p = 0.002), while it negatively
correlated with doxorubicin dose (p = 0.00001).
Disruption of salivary bacterial communities during
chemotherapy correlates with mucositis severity
The oral microbiome was longitudinally evaluated by se-
quencing of salivary and mucosal 16S rRNA gene ampli-
cons and salivary internal transcribed spacer (ITS)-1 DNA
amplicons. Chemotherapy disrupted the oral microbiome
with the most severe changes seen in salivary bacterial
communities. Salivary bacterial alpha-diversity decreased
during the cycle (p = 0.01 at V3 and p = 0.009 for linear
change) and at the visit with the most severe mucositis
(Fig. 3a, p = 0.001). Mucosal bacterial community diversity
was only minimally affected, with a small increase seen at
V2 (p = 0.042), while salivary fungal community diversity
did not change during chemotherapy (Fig. 3a). Changes
over time in salivary bacterial diversity modelled with
orthogonal polynomial contrasts showed a correlation of
the linear change with the dose of 5-FU and intake of a
multi-dose antibiotic, and of the quadratic change with
docetaxel and cisplatin doses (Additional file 2: Table S3).
To better understand the contributions of different pre-
dictors to changes in salivary bacterial diversity and evalu-
ate their effect at each time point during the cycle, we also
conducted a by visit analysis, calculating the change in di-
versity from each visit to baseline (Fig. 3b). This analysis
showed that at V2, there was a trend for a correlation
between decreased salivary bacterial diversity with higher
cisplatin dose and intake of acid inhibitors. At V3, de-
creased diversity correlated with higher OMAS scores at
the same visit (p = 0.003), a higher docetaxel dose (p =
0.008), and use of acid inhibitors (p = 0.004). The use of a
multi-dose antibiotic and the dose of cisplatin showed a
trend for a negative correlation with diversity. At V4, the
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use of a multi-dose antibiotic (p = 0.0005) was associated
with a decrease in diversity. A linear regression analysis was
run considering the change in diversity at V3 as dependent
variable and OMAS score, the use of multi-dose antibiotic
and use of acid inhibitors as predictors. This analysis
showed that OMAS (β = − 0.300, p = 0.046) and acid in-
hibitor use (β = − 0.301, p = 0.045), but not antibiotic use,
remained significantly associated with the change in diver-
sity at V3. In summary, different factors appeared to have
influenced salivary bacterial alpha-diversity with changes at
V3 associated with mucositis severity and acid inhibitor use
and at V4 with the intake of a multi-dose antibiotic.
Echoing the changes seen in alpha-diversity, salivary
bacterial community structure (beta-diversity) was also
disturbed during chemotherapy (Fig. 3c). Mucosal
bacterial communities followed a similar trend as their
salivary counterparts but their changes were not greater
than those of non-cancer controls. The structure of
salivary fungal communities was not disturbed by
chemotherapy (Fig. 3c).
Fig. 2 Changes in salivary flow rate and peripheral and oral neutrophils during chemotherapy and correlation of these changes with oral
mucositis severity. a, b Salivary flow rate (SFR) in control and cancer subjects. A statistically significant increase in SFR was seen in cancer subjects
at V3 and V4 compared to baseline. Also, the linear change (L) in SFR during chemotherapy was significant. c A correlation between the negative
quadratic change in OMAS (low, high, low) and the positive linear change in SFR in cancer subjects indicating SFR increased concomitant to or
following mucositis. Each data point in the plot represents the change in a subject and was generated by transforming data from each visit according
to orthogonal polynomial contrast coefficients followed by aggregation of the data from the four visits. d, e The change in peripheral neutrophils in
control and cancer subjects. A statistically significant decrease during chemotherapy was seen at V3 and V4 compared to baseline. Also, the change
during chemotherapy modelled with a quadratic polynomial contrast (Q) was significant. f A correlation between the positive quadratic change in
peripheral neutrophils (high, low, high) and the positive linear change in OMAS indicating a correlation between neutrophil depletion and mucositis
severity. g, h The change in oral neutrophils in control and cancer subjects. A statistically significant decrease was seen at V2 during chemotherapy. i A
positive correlation between the linear change in oral neutrophils and mucositis severity. * indicates a p value < 0.05 and ** < 0.01
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To inquire which patient factors were associated with
disruptions in community structure, the ThetaYC
distances between baseline to each visit, indicating the
magnitude of change, were evaluated for a correlation
with clinical characteristics (Fig. 3d). This analysis
showed that the degree of salivary bacterial community
disruption at V2 correlated with cisplatin dose (p =
0.004). At V3, salivary bacterial ThetaYC distances posi-
tively correlated with the degree of mucositis severity (p
= 0.000005), with the doses of 5-FU (p = 0.00007) and
Fig. 3 Changes in the oral microbiome during chemotherapy and in relation to the development of oral mucositis. a Bacterial and fungal
microbiome diversity in control and cancer subjects. Salivary bacterial diversity decreased at visit 3 compared to baseline and also the linear
change (L) in diversity was significant. Decreased salivary bacterial diversity was also seen at the visit with the highest OMAS. Mucosal bacterial
diversity increased at V2, while no changes were seen in salivary fungal communities. b Variables significantly correlated with the change in
salivary bacterial diversity at each visit when compared to baseline. Data represent Spearman correlation coefficients with p values in parenthesis.
Colored cells show correlations significant after adjustment for multiple comparisons via the FDR method. c Changes in community structure as
measured by the ThetaYC distance from baseline (V1) to each visit. Black data points indicate changes in control subjects and color data points
indicate cancer subjects. ** indicates a p value < 0.01 when comparing to control subjects via Mann-Whitney Rank tests. d Variables significantly
correlated with changes in salivary and mucosal bacterial community structure (1-ThetaYC distance from baseline to each visit). Data represent
Spearman correlation coefficients with p values in parenthesis. Colored cells show correlations significant after adjustment for multiple
comparisons via the FDR method
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docetaxel (p = 0.0001) and with the use of acid inhibitors (p
= 0.002). Linear regression using salivary bacterial ThetaYC
distances at V3 as the dependent variable and OMAS
scores and acid inhibitor use as predictors showed both var-
iables remained independently associated with community
structure change (OMAS β = 0.527, p = 0.0002 and acid in-
hibitor β = 0.287, p = 0.033). At V4, salivary bacterial com-
munity disruption correlated with mucositis severity (p =
0.002) and with 5-FU (p = 0.005) and docetaxel (p = 0.007)
doses. Surprisingly, antibiotic use only showed a trend for a
correlation with salivary bacterial community disruption,
and this occurred only at V4 (p values below 0.05 but not
significant after adjustment for multiple testing). A linear
regression analysis evaluating the effect of OMAS,
multi-dose antibiotics, and acid inhibitors on ThetaYC dis-
tances at V4 showed that when the effect of each of the
three predictors was adjusted for the effect of the others,
OMAS (β = 0.347, p = 0.014) and antibiotics (β = 0.281, p
= 0.048) remained significant below a 0.05 p level. For mu-
cosal communities, the only significant correlation seen
was between ThetaYC distances at V4 and antibiotic use. A
correlation trend was seen between mucosal ThetaYC dis-
tances at V3 with cisplatin dose and antibiotics. Overall,
these results show that mucositis severity and acid inhibitor
use were the main predictors associated with salivary bac-
terial community structure disruption during the cycle. An-
tineoplastic doses were also associated with ThetaYC
distances, but it should be noted that their independent as-
sociation could not be evaluated as they are highly corre-
lated with OMAS scores. Antibiotics seemed to only affect
the microbiome at V4 having a greater effect on mucosal
communities than on their salivary counterparts.
We next asked if disruption of salivary bacterial com-
munity structure occurred in a consistent direction
among subjects as visualized by PCoA plots (Additional
file 1: Figure S2). At V2, there was no significant separ-
ation of samples from baseline communities. At V3 and
V4, there was a significant separation of the correspond-
ing data clouds from baseline samples, although not all
microbiomes changed in a uniform direction (Additional
file 1: Figure S2A–B, p = 0.006 at V3 and p = 0.003 at
V4). Although microbiome changes were heterogeneous
among subjects, microbiome variability along axis 2 in
both the V3 and V4 plots (Additional file 1: Figure S2A–
B) correlated with OMAS score, doses of 5-FU, and
docetaxel, with receiving a multi-dose antibiotic prior to
V3, and with changes in alpha-diversity.
Changes in the proportions of individual taxa during
chemotherapy were also evaluated. Additional file 1: Fig-
ure S2C shows the number of taxa that significantly
changed at each visit, with the greatest number of al-
tered taxa seen in salivary bacterial communities at V3
and V4. Additional file 1: Figure S3 and Additional file
3: Table S4 show the identity of these taxa. At V3, all
changes in saliva were due to significant decreases in
relative abundance. Several Gram-negative species from
the genera Prevotella, Selenomonas, Leptotrichia, Tan-
nerella, Campylobacter, Capnocytophaga, and Parvimo-
nas showed a trend to increase in relative abundance at
V3, but no species reached significance, highlighting the
heterogeneity among individuals in the species that re-
placed those that decreased. At V4, we observed both
significant increases and decreases in abundance.
Taken together, these results show that the salivary
bacterial microbiome was profoundly altered during
chemotherapy. While intake of multi-dose antibiotics
and acid inhibitor use during the cycle were associated
with some of the observed microbiome modifications,
disruption of salivary bacterial communities was also in-
dependently associated with oral mucositis severity. The
total doses of 5-FU, docetaxel, and cisplatin, associated
with more severe mucositis, also correlated with greater
salivary bacteriome disruption.
Oral mucositis is associated with oral bacteriome
dysbiosis
To evaluate the longitudinal covariation of microbial taxa
and clinical variables during chemotherapy, we conducted a
multilevel multivariate sparse partial least square analysis
focusing on bacterial species enriched or depleted in ac-
cordance with mucositis severity. Figure 4a shows the cor-
relations between the longitudinal change in salivary
bacterial proportions and clinical variables, including
OMAS scores. Mucositis severity positively correlated with
enrichment of 3 salivary Gram-negative species (taxa 1 to 3
in Fig. 4a), namely Fusobacterium nucleatum subsp. vincen-
tii, an uncultured Clostridiales, and Treponema maltophi-
lum, all taxa associated with other oral inflammatory
conditions [19]. Mucositis severity also correlated with a
decrease in proportions of 24 salivary bacterial species (taxa
4 to 27 in Fig. 4a), among them abundant commensals
from genera typically associated with oral health such as
Streptococcus, Actinomyces, Gemella, Granulicatella, and
Veillonella [19, 22]. Consistent with previous analyses (Fig.
2), mucositis severity positively correlated with SFR and
oral neutrophils (Fig. 4a). It should also be noted that the
intake of a multi-dose antibiotic did not correlate with
changes in the same salivary bacteria associated with
OMAS. This result further confirmed antibiotic treatment
was not the cause of mucositis-associated dysbiosis.
A similar analysis of mucosal bacterial communities
found that changes in only a few taxa correlated with
mucositis severity (Fig. 4b). Changes, however, were
consistent with those seen in saliva, with enrichment
of the Gram-negative, inflammation-associated Prevo-
tella oris [19] and lower abundance of Streptococcus,
Veillonella, and Actinomyces species as OMAS scores
increased (Fig. 4b).
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Taken together, these results revealed that mucositis is
associated with depletion of prevalent health-associated
commensals (likely symbionts) and enrichment of Gram-
negative species typically enriched during oral inflamma-
tion (likely pathobionts). These changes are reminiscent of
dysbiotic shifts seen in other oral inflammatory conditions
such as gingivitis and periodontitis [19], although the
changes are not directly related to these conditions as
mucositis did not correlate with the presence of severe
periodontitis.
The antimicrobial activity of antineoplastics is unlikely to
explain chemotherapy-associated dysbiosis
We found that the change in relative abundance of many
species associated with mucositis (in Fig. 4a, b) also cor-
related with the use and dose of specific antineoplastics
(Additional file 1: Figure S4A). For instance, depletion of
Streptococcus salivarius during mucositis correlated with
higher doses of 5-FU and docetaxel (p = 0.004 in both
cases). Additional file 1: Figures S4B and S4C show taxa
depleted during mucositis in subjects taking 5-FU, but
Fig. 4 Longitudinal covariation of bacterial relative abundances and clinical signs of oral mucositis during chemotherapy. a A circle correlation
plot depicting covariation of salivary bacterial abundances with oral mucositis severity (OMAS) and other significant clinical variables, as determined via
multi-level sPLS analysis. Bacterial species appear as red circles and clinical variables are shown as blue triangles. Data points were placed in the plot
according to their correlation with the two main components. Positively correlated variables follow the same direction from the origin. The greater the
distance from the origin, the stronger the association. Only variables with a correlation coefficient greater than 0.4 are shown. Red numbers and
corresponding names indicate bacterial species positively correlated with OMAS (enriched as mucositis severity increased), while black numbers and
names indicate bacterial species negatively correlated with OMAS (depleted during severe mucositis). SFR salivary flow rate, MD AB multi-dose antibiotic
intake; b a similar analysis done for mucosal bacterial taxa. Bacterial species appear as orange circles and clinical variables as blue triangles. Red numbers
and names indicate species positively correlated with OMAS, while black numbers and names indicate bacterial species negatively correlated with OMAS
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that did not change in subjects on doxorubicin who also
presented with mucositis, albeit of less severity. These
results raised the possibility that the antimicrobial activ-
ity of specific antineoplastics was contributing to the se-
lective depletion or enrichment of oral bacteria during
chemotherapy-induced mucositis. Indeed, when we ex-
posed salivary communities to physiological concentra-
tions of 5-FU or 5-FU and docetaxel, we observed a
decrease in viability of the total culturable community
after a 2-h incubation suggesting these drugs have the
potential to modify the microbiome (Additional file 1:
Figure S4D). We hypothesized that if 5-FU was respon-
sible for the dysbiotic changes seen during chemother-
apy, in particular those shifts associated with mucositis,
then depleted taxa should be susceptible to the drug
while enriched species would be resistant. To test this,
bacterial strains of the depleted S. salivarius, Streptococ-
cus parasanguinis, Veillonella atypica, and Veillonella
rogosae and the enriched Fusobacterium nucleatum were
exposed to 5-FU. After a 2-h incubation, however, only
Veillonella atypica showed decreased viability at the
same physiologic concentration (7.7 μM) tested with
whole saliva (Additional file 1: Figure S4E). In fact, many
of the commensals depleted during mucositis were resist-
ant to killing by 5-FU even at drug concentrations likely to
be above the physiologic range (e.g., 770 μM). The ability
of 5-FU to inhibit the growth of S. salivarius and F. nuclea-
tum was also tested with these evaluations showing that
even high concentrations of 5-FU did not completely in-
hibit S. salivarius, while the growth of F. nucleatum was
inhibited by all concentrations tested (Additional file 1: Fig-
ure S4F–G). Since taxa negatively correlated with 5-FU
and mucositis were not consistently sensitive to 5-FU
exposure and a species enriched during mucositis was not
resistant to the drug, we conclude that an antimicrobial ef-
fect of 5-FU is unlikely to explain the microbiome dysbiosis
associated with mucositis. Chemotherapeutics, however,
could still temporarily modify the oral microbiome, espe-
cially while salivary drug concentrations are in the high
range, but these changes do not seem to be associated with
mucositis-specific shifts.
Mucosal lesions did not differ in their microbiome from
healthy mucosa
The analysis of mucosal communities used combined li-
braries from sites with different clinical appearance
(healthy, erythematous, ulcerated) obtained from the same
subject. An analysis using separate libraries (see list of li-
braries in Additional file 2: Table S5) was also conducted
to explore whether mucosal lesions harbored a micro-
biome distinct from their subject-matched healthy site
counterparts. We did not observe differences in either
alpha-diversity (Additional file 2: Table S6) or in the abun-
dance of individual taxa when comparing visit-matched,
within-subject, mucosal communities with different
clinical appearance (healthy vs erythematous or healthy vs
ulcerated). This result indicates that mucosal surface
changes were not selecting for a specific microbiome
colonization at the lesion sites but rather mucositis-asso-
ciated dysbiosis was affecting the mouth as a whole.
The oral epithelium responds to chemotherapy by
upregulating genes involved in innate immune responses
and apoptosis
Since little information exists on genes and pathways
mediating oral mucosal injury, we conducted a gene ex-
pression analysis in a subset of 14 subjects comparing
oral epithelial transcript levels between baseline and V3.
The clinical characteristics of the subjects analyzed are
shown in Additional file 2: Table S7. SAM analysis
showed 158 upregulated and two downregulated genes
at V3 (> 1.5-fold) (Additional file 4: Table S8). Although
there was substantial variability in the response of sub-
jects, this was not related to the type of chemotherapeu-
tic regimens subjects were taking according to clustering
analysis. Figure 5a shows a summary of upregulated
gene ontology (GO) term categories (for a complete list
see Additional file 5: Table S9), which included genes in-
volved in epidermis development, apoptosis and cell
death, proteolysis, immune responses, and response to
stress. Figure 5b shows the main genes involved in in-
nate immune responses that were upregulated. These in-
cluded TNF, which is a key inflammatory mediator that
leads to activation of nuclear factor κB (NF-κB) but
could also activate apoptosis via the extrinsic pathway or
induce necroptosis [23]. Other genes involved in epithe-
lial innate immune responses to microbial commensals
such as IL17C, CCL20, CXCL2, DEFB4A, and DEFB103A
were also upregulated suggesting a microbiome influ-
ence on mucosal responses during chemotherapy.
Another category of genes upregulated that could have a
role in mediating mucosal damage was genes related to
apoptosis (Fig. 5c). Of particular interest was the upreg-
ulation of PMAIP1, the gene encoding the proapoptotic
Bcl2 homology 3 (BH3)-only protein NOXA, which acti-
vates the intrinsic apoptosis pathway [24], and has been
shown to mediate cisplatin-induced cell death [25].
Potential for bacterial dysbiotic changes to affect
epithelial responses
We next explored the potential for dysbiotic microbiome
changes associated with mucositis severity to affect epi-
thelial responses. As Fig. 5d shows, exposure of a 3D
multilayer oral epithelial construct to the potential sym-
biont S. salivarius, depleted during mucositis, provoked
minimal induction of innate immune response genes. In
contrast, challenge of epithelial tissues with a similar
load of the potential pathobiont F. nucleatum, associated
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with more severe mucositis, produced a dramatic upregu-
lation of TNF, IL17C, CCL20, and CXCL2. We also
observed that F. nucleatum induced an upregulation of
PMAIP1 and, consistent with this effect, tissues displayed
death of cells in the apical layer (Fig. 5e). These results
suggest that dysbiosis triggered by chemotherapy could
affect epithelial responses and may play a role in the
course of oral mucositis lesions.
Fig. 5. Epithelial responses to chemotherapeutic treatment and potential for commensals to modulate mucosal response. Changes in the oral
epithelial transcriptome during chemotherapy (baseline to V3) were evaluated in 14 subjects via DASL-whole genome arrays. a A scatter plot
showing significantly upregulated gene ontology (GO) terms summarized using REVIGO. Size of each circle represents GO term frequency (log
scale) and color its p value (log scale), with lower p values in blue. b genes related to the immune response that were upregulated more than
twofold during chemotherapy. c Genes related to apoptosis upregulated more than twofold during chemotherapy. d The expression of selected
immune genes as evaluated via real-time PCR after exposure of a 3D multilayer oral epithelial construct to Streptococcus salivarius ATCC 9222 (Ss)
or Fusobacterium nucleatum subsp. vincentii ATCC 49256 (Fn). e Expression of the proapoptotic gene PMAIP1 (NOXA) as measured via real-time
PCR and micrographs depicting multilayer oral epithelial constructs stained with a fluorescent TUNEL assay to evaluate cell death. TUNEL-positive
cells appear green and nuclei in blue. Bar = 50 μM
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Discussion
Despite the adverse clinical impact of oral mucositis,
there is insufficient knowledge on its pathophysiology.
Enhanced understanding of events that mediate oral mu-
cosal damage and whether microbial signaling modifies
the response to antineoplastics is important for the
future development of novel therapies. To our know-
ledge, our work represents the most comprehensive
characterization to date of changes in the human oral
environment during chemotherapy in relation to oral
mucositis. Our study cohort included patients undergo-
ing treatment based on either 5-FU or doxorubicin.
Although both groups developed oral mucositis, its inci-
dence was higher in the 5-FU group with a highly sig-
nificant correlation seen between the total dose of 5-FU
and the severity of lesions. 5-FU is an anti-metabolite
drug widely used either alone or as a foundational thera-
peutic in combination treatment regimens for a range of
cancers, including colorectal, breast, and cancers of the
aerodigestive tract [7]. A recently developed animal
model showed that 5-FU induces atrophy of the oral
mucosa with reduced proliferation, increased cell death,
upregulation of pro-inflammatory mediators, and
compromised barrier integrity [26]. The mechanisms by
which 5-FU alone or in combination with adjunct
chemotherapeutics exerts its toxic effects on the human
oral mucosa, however, remain incompletely understood,
with the role of the microbiome in oral mucositis almost
entirely unexplored.
Our work demonstrates that the oral microbiome is
disrupted by chemotherapy. Although we expected
chemotherapy to affect the oral mycobiome due to myelo-
suppression, we did not observe major changes in the
composition of fungal communities. Instead, it was the
oral bacteriome that displayed major modifications. These
changes were of greater magnitude in salivary communi-
ties, but were also detected in mucosal samples. Shifts in
the oral bacteriome were strongly correlated with mucosi-
tis severity. Bacteriome shifts, however, affected the mouth
as a whole and were not specific to the surfaces of lesions
as we did not detect any differences in the mucosal bacter-
ial communities present at healthy, erythematous, or
ulcerated sites. It should be noted, however, that since
swabs were used to sample mucosal lesions, there could
have been subsurface microorganisms in lesions not
captured by our sampling approach.
An exploration of possible causes of bacteriome shifts
found that the use of a multiple dose antibiotic corre-
lated with decreased salivary bacterial diversity but
showed only a weak correlation with changes in salivary
bacterial community structure. Antibiotic intake mostly
affected the oral microbiome at the last visit (V4) and its
effect was independent from mucositis-associated dys-
biotic shifts. Furthermore, a single-dose prophylactic
antibiotic exposure did not correlate with oral micro-
biome changes. This lack of a major effect of antibiotics
on the oral microbiome is not surprising, as previous
studies indicate the oral microbiome is resistant to
change after systemic antibiotic administration, in con-
trast to gut communities, which are easily disrupted by
antibiotics [27]. Microbiome changes during chemother-
apy and mucositis could be neither explained by im-
paired salivary flow, which in fact was increased during
chemotherapy and positively associated with mucositis
severity. This result contrasted with previous reports in
which patients undergoing repeated chemotherapy had
decreased SFR [15]. The discrepancy with our results is
probably due to the fact that our cohort was comprised
of patients who were either chemotherapy-naïve or in
their first cycles of treatment. It is possible that repeated
exposure to antineoplastics could cause induction of
temporary glandular damage therefore affecting SFR.
Similarly, dysbiotic microbiome shifts were not related
to decreased oral granulocyte availability, which in fact
was positively correlated with more severe mucositis. In-
creased oral neutrophils during mucositis may be the re-
sult of upregulation in chemoattractants such as CXCL2
by the epithelium, as seen in our transcriptome data, in
combination with barrier defects through which neutro-
phils escape tissues. Furthermore, evaluation of a direct
antibacterial effect of chemotherapeutic drugs did not
support the possibility that chemotherapeutics, in par-
ticular 5-FU, were responsible for microbiome shifts as-
sociated with mucositis, although 5-FU showed
antimicrobial activity against whole salivary communities
and against a few of the species tested. Salivary concen-
trations of 5-FU have been measured at approximately
77 μM 12 min after the start of 5-FU administration, but
concentrations rapidly decrease to about 7 μM after 3 h
and become undetectable minutes after the end of a
22-h infusion [28].Based on our results, it is thus pos-
sible that for a short period of time during 5-FU admin-
istration, the viability of selected oral bacteria is affected
by the drug, but salivary 5-FU concentrations rapidly de-
cline allowing oral commensals to recover. In addition,
it should be noted that most study subjects received
5-FU within a maximum 5-day window, while most of
the microbiome changes associated with mucositis were
seen to occur at visits 3 and 4, which were days apart
from the last infusion. Based on the salivary drug kin-
etics described above, it is therefore unlikely that mu-
cositis-associated microbiome shifts were due to a
direct antibacterial effect of 5-FU. In support of this,
we did not observe that microorganisms whose deple-
tion correlated with high 5-FU doses and more severe
mucositis were consistently sensitive to 5-FU, while
the growth of F. nucleatum, a microorganism
enriched during mucositis, was inhibited by the drug.
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The correlation of microbiome shifts and mucositis is
in agreement with a previous study that evaluated
changes in the oral mucosal bacterial communities in
children undergoing chemotherapy, finding greater
microbiome modifications in children that developed
oral mucositis [29]. This prior study, however, did not
define specific species associated with lesion develop-
ment. We found that shifts in bacterial communities
during mucositis consist of depletion of abundant spe-
cies from genera associated with health and enrichment
of Gram-negative species linked to other oral inflamma-
tory conditions [19]. Mucositis-associated microbiome
shifts may have resulted from the release of inflamma-
tory products into the oral environment after
chemotherapy-induced damage and inflammation. Bac-
terial species from genera found enriched in mucositis
are known to thrive using inflammatory products as nu-
trients [30, 31], and therefore, the observed mucositis-
associated microbiome shifts could have resulted from
alterations in oral nutritional resources that promote the
growth of these Gram-negative species.
To better understand epithelial cellular events altered by
chemotherapy and potential contributors to oral mucosal
injury, we performed a global gene expression analysis of
changes in the oral epithelium from baseline to V3. Al-
though the specific sites sampled were not affected by mu-
cositis, most subjects presented with lesions in other areas
of the mouth at the time of sampling. One upregulated cat-
egory was that of genes involved in the innate immune re-
sponse, including here TNF, IL17C, CXCL2, and CCL20,
which are cytokines typically induced in epithelial tissues by
stimulation with microorganisms, but not part of the re-
sponse of cell lines after an antineoplastic challenge [32–
36]. This suggested that some of the responses seen in vivo
were the result of microbial-host cross talk. In vitro chal-
lenge of a 3D oral epithelial construct with F. nucleatum, a
microorganism associated with more severe mucositis, con-
firmed the potential for a dysbiotic microbiome to contrib-
ute to upregulation of these innate immune response genes
during chemotherapy. In contrast, S. salivarius, a micro-
organism depleted during mucositis, only promoted a slight
upregulation or had no effect on innate immunity media-
tors. The role microbially induced innate immune re-
sponses could play in amplifying oral epithelial damage
during chemotherapy warrants further investigation.
An expected category of upregulated genes in the oral
epithelium during chemotherapy was that of apoptosis-re-
lated genes. Among them, the pro-apoptotic gene PMAIP1
(NOXA) is known to mediate antineoplastic-induced cyto-
toxicity [25]. NOXA is a BH3s death sentinel that acts by
directly inducing stepwise, bimodal activation of BAX–
BAK, which mediate permeabilization of mitochondria,
followed by the release of cytochrome c and caspase activa-
tion [24]. NOXA also binds to the anti-apoptotic protein
MCL-1 and may induce apoptosis by preventing its activity
[24, 37, 38]. PMAIP1 is upregulated in gastric epithelial
cells upon Helicobacter pylori infection, which suggests a
link between microbial sensing and PMAIP1 transcription
[39]. Unexpectedly, we also observed that in vitro challenge
of oral epithelial cells with F. nucleatum upregulated ex-
pression of PMAIP1 and consistent with this, F. nuclea-
tum-challenged tissues displayed cell death markers. This
suggested that the upregulation of signals leading to cellular
death could also occur in response to oral dysbiosis, which
may serve to aggravate epithelial injury.
Another factor identified as associated with mucositis
was wearing a removable prosthesis. Contact of a den-
ture with oral tissues may constitute a mechanical insult
that aggravates antineoplastic-driven epithelial injury.
Dentures are also known to promote the overgrowth of
oral commensals, which in turn could modify mucosal
damage [40]. Additional factors associated with a linear
increase in mucositis severity were smoking and steroid
use during the cycle. Both smoking and steroids are
likely to modify innate immune responses of mucosal
tissues that are important for controlling dysbiosis [41,
42], and may play a role in mucositis pathophysiology.
Conclusions
In summary, our work shows that the severity of oral mu-
cositis lesions correlates with the degree of oral micro-
biome dysbiosis, with enrichment of potential Gram-
negative pathobionts and depletion of health-associated
symbionts in severe mucositis. These microbiome alter-
ations resemble the dysbiotic shifts associated with other
oral diseases in which changes in the environment and
nutrient resources, due to inflammation, induce the out-
growth of low abundant species, which in turn dysregulate
host defenses leading to damage [20]. Indeed, F. nucleatum,
a potential pathobiont enriched as mucositis became more
severe, showed an ability to induce pro-inflammatory and
apoptotic responses in a 3D oral epithelium model, while S.
salivarius, a potential symbiont depleted in severe mucosi-
tis, was tolerated. While antineoplastics represent the
primary initiators of mucositis, our observations also sug-
gest that antineoplastic-triggered inflammation may induce
microbiome disruptions and that such dysbiotic micro-
biome could play a role in the clinical course of lesions ag-
gravating epithelial injury. Further studies are warranted to
elucidate whether interfering with dysbiotic events could
reduce oral mucositis incidence and/or severity.
Methods
Study design
This observational prospective study with two cohorts
was approved by the Institutional Review Board at UConn
Health (IRB number IE-11-037 J-2) and conformed with
STROBE guidelines. Written informed consent was
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received from all participants. Additional file 1: Figure S1
shows the study design and inclusion and exclusion cri-
teria. Subjects planned to or already receiving chemother-
apeutic treatment for a solid tumor either on a
5-fluorouracil (5-FU)- or a doxorubicin-based regimen
were recruited at the Neag Comprehensive Cancer Center
of UConn Health and at the Helen and Harry Gray Can-
cer Center at Hartford Hospital. Every effort was made to
recruit chemotherapy-naïve subjects. From the 49 enroll-
ments in the cancer cohort, 32 were chemotherapy-naïve
while 17 had already completed at least one previous
cycle. Thirty non-cancer controls were enrolled from the
general local population through the UConn Health Den-
tal Clinical Research Center. Cancer subjects were seen at
four visits which included a baseline visit completed prior
to subjects commencing chemotherapy, and three more
visits (V2–V4) within 14 ± 2 days after commencing treat-
ment. Control subjects were seen at two visits, including a
baseline and a visit within 14 ± 2 days (V4).
Collection of demographic and medical data and oral
evaluation
Medical information was obtained via questionnaires
and from medical charts. All subjects received at base-
line an oral evaluation including assessment of the pres-
ence of periodontitis via the Community Periodontal
Index of Treatment Needs (CPITN) [43], presence and
type of prosthetic restorations, number of teeth, and
presence of visible cavitated carious lesions. In addition,
at all visits subjects were evaluated for the presence and
severity of mucositis per the World Health Organization
(WHO) scale, which assesses oral soreness, erythema,
ulceration, and ability to eat using a 0–4 scale, giving a
single score for the entire oral cavity [44]. A score of 0
indicates no signs or symptoms; 1 indicates erythema
and soreness; 2 indicates ulcers, able to eat solids; 3 indi-
cates ulcers, requires liquid diet (due to mucositis); and
4 indicates ulcers, alimentation not possible (due to mu-
cositis). A second mucositis assessment method, the
Oral Mucositis Assessment Scale (OMAS) was also used
[45]. The OMAS provides an objective assessment of
oral mucositis based on an evaluation of the appearance
and the extent of redness and ulceration in various areas
of the mouth. Nine oral mucosal sites were evaluated for
presence and severity of mucositis ulcerative lesions
assigning to each site a score from 0 to 3 depending on
lesion size, and for severity of erythema, assigning each
site a score from 0 to 2. These scores were then aggre-
gated per site and therefore each site could have a score
ranging from 0 to 5. Scores from all nine sites were then
aggregated for a total mouth score ranging from 0 to 45.
Aggregated total mouth scores were used for analysis. At
all visits, a subjective evaluation of oral dryness was also
conducted [46], and an assessment of the amount of
plaque on teeth, as determined via the Plaque Index of
Silness and Löe [47].
Salivary flow rate determination and collection of
samples for microbiome evaluation
At each visit, unstimulated saliva and mucosal swabs were
collected for microbiome evaluation. Participants were
instructed to avoid eating or drinking anything other than
water for 1 h prior to each study visit. Unstimulated saliva
was collected for 5min by having subjects lean forward
over a sterile funnel attached to a sterile vial placed on ice.
Saliva was weighted to determine salivary flow rate, and
then aliquoted and centrifuged at 6000×g for 10min.
Supernatants were removed and pellets stored at − 80 °C.
Mucosal swab samples were collected in subjects present-
ing mucosal health by swabbing the entire right and left
buccal mucosa for 10 s each with a single CatchAll™ swab.
In subjects presenting with mucosal lesions, separate
swabs were collected from healthy mucosal areas, ery-
thematous tissue, and areas with ulceration. Swabs were
immediately swirled in a tube containing 500 μL of TE
buffer (20mM Tris pH 7.0, 2 mM EDTA) pressing against
the tube walls to release the swab contents. Samples were
then stored at − 80 °C.
Collection of samples for oral epithelium transcriptome
analysis
Oral mucosal cytology samples were collected using a
Cytobrush™, which was pressed and rotated against a
healthy mucosal area for 60 s. If the procedure lead to
mucosal bleeding, the sample was discarded to avoid
contamination by cells beyond the epithelium. After col-
lection, the brush was swirled in 1mL of RNAProtect
(Qiagen), pressing against the tube walls to release the
brush contents. Cells were pelleted at 8000×g for 20
min, snap-frozen, and stored in liquid nitrogen.
Evaluation of blood and oral neutrophil counts
Total counts and percentages of neutrophils were ob-
tained from complete blood counts performed by the
hospital laboratory using an automated Beckman
Coulter analyzer. Oral cells were collected at all study
visits by asking subjects to rinse with 10 mL of a
bicarbonate solution for 30 s. Oral rinse samples were
centrifuged at 1258×g for 15 min and pellets were re-
suspended in Hanks’ Balanced Salt solution supple-
mented with 2 μg/ml acridine orange. Granulocytes,
most of which are neutrophils, characteristically stained
as multilobulated cells with this nuclear stain, were
enumerated in a hemacytometer under a fluorescence
microscope [48].
Hong et al. Microbiome            (2019) 7:66 Page 13 of 18
DNA extraction for microbiome evaluation
DNA was extracted separately for bacterial and fungal
microbiome evaluation. For bacteria, we followed a pre-
viously described procedure using lysozyme and protein-
ase K treatment and the DNeasy Blood and Tissue kit
(Qiagen) [49]. For fungi, the DNA extraction protocol
involved bead beating with a matrix containing Lysing
Matrix B (MP Biomedicals) and very high density 0.5
mm yttrium-stabilized zirconium oxide (95% ZrO2 + 5%
Y2O3) grinding media (YSZ) (Glen Mills Inc, Clifton,
NJ), followed by extraction using the FastDNA SPIN
KIT (MP Biomedicals), as previously described [50].
Amplification and sequencing of 16S rRNA gene and ITS-
1 DNA
Amplicon libraries of the 16S rRNA gene V1–V2 hypervar-
iable regions were generated in triplicate using fusion
primers which included universal primers 8F AGAG
TTTGATCMTGGCTCAG or 361R CYIACTGCTGCC
TCCCGTAG [51]. PCR conditions have been described
previously [49]. For mycobiome characterization, fusion
primers containing fungal-specific ITS1F forward primer
(CTTGGTCATTTAGAGGAAGTAA) or ITS2 reverse pri-
mer (GCTGCGTTCTTCATCGATGC) were used to amp-
lify ITS-1 sequences in triplicate, as previously described
[50]. Combined libraries were further purified and se-
quenced using 454 Titanium chemistry and the 454-GS-
FLX sequencing platform (454 Life Sciences, Branford,
CT). Since mucosal samples did not consistently yield
ITS-1 PCR products, probably due to low fungal load, only
saliva samples were evaluated via ITS-1 sequencing.
Processing of sequences and taxonomic classification
16S rRNA gene reads were processed in mothur [52].
Primers and barcodes were trimmed followed by re-
moval of sequences shorter than 200 bp, with homopoly-
mers greater than eight nucleotides or ambiguous base
calls. Sequences were then filtered using a 50 bp sliding
window approach and an average quality score threshold
of 35 [53]. Chimeric sequences were removed with
UChime [54], in mothur. Sequences were then classified
to species level by using the classify.seqs command and
the Human Oral Microbiome Database (HOMD) V14.5
as reference. Parameters used were: method = knn, search
= blast, gapopen = − 5, gapextend = − 5, match = 4, mis-
match = − 5, numwanted = 1, following recommendations
by Al-Hebshi et al. [55]. This taxonomy assignment algo-
rithm was validated by classifying HOMD reference
sequences trimmed to include only the V1–V2 region
against the HOMD full-length reference sequence data-
base. With a few exceptions, all V1–V2 short sequences
were correctly classified in the validation test. However, the
following species could not be discriminated from each
other: Lactobacillus casei and Lactobacillus rhamnosus;
Veillonella parvula and Veillonella dispar; Streptococcus
mitis, Streptococcus pneumoniae, and Streptococcus sp.
HOT423; and Neisseria flavescens and Neisseria subflava.
Counts for species that could not be correctly identified
were aggregated.
ITS-1 reads were also processed in mothur [52]. Se-
quences were trimmed and quality filtered and chimeras
removed as described for 16S rRNA sequences.
Sequences were then classified to genus level by using
the classify.seqs command and a modified version of the
Findley et al. database [56] as a reference, employing the
recommended parameters (https://www.mothur.org/
wiki/Findley_ITS_Database). Prior to this, a curation of
the Findley et al. database was conducted to join syno-
nym taxa under one preferred name [57]. To accomplish
this, reference sequences from synonym taxa were com-
pared via BLAST against NCBI’s nucleotide type strain
database and against the Fungal Metagenomics Project
database. After confirming their genus identity, Gueo-
myces sequences were included under Trichosporon;
Lewia under Alternaria; Valsa under Cytospora; Copri-
nellus and Coprinopsis under Coprinus; Erythrobasidium
under Rhodotorula; Cochliobolus under Curvularia; Filo-
basidium, Cystofilobasidium and Dioszegia under Cryp-
tococcus; and Emericella under Aspergillus. In addition,
sequences of Cladosporium, Toxicocladosporium, Aureo-
basidium, Kabatiella, Scleroconidioma, and Candida
were added as they were underrepresented in the data-
base. Malassezia and Candida ITS-1 sequences were
further classified to species level, using curated and
aligned reference libraries and the software package
pplacer [58], as previously described [56]. A total of 691
saliva- and mucosa-derived libraries were sequenced. All
sequences are available at the Short Reads Archive
(Accession number PRJNA399163).
Alpha and beta-diversity estimates for 16S rRNA gene
and ITS-1 amplicon data
16S rRNA gene libraries were subsampled at 3074 reads
and ITS-1 reads at 1338 reads. Rarefaction curves were
generated via the R package vegan and can be found in
Additional file 1: Figure S5. Most curves were starting to
become asymptotic at the thresholds used for subsampling.
Community diversity was evaluated via the non-parametric
Shannon Index and community structure via the Yue-Clay-
ton Theta Index (ThetaYC) as calculated in mothur. These
metrics were constructed based on species-level taxonomic
units for 16S rRNA gene reads and genus-level for ITS-1
(with the exception of Malassezia and Candida that were
speciated). Mucosal communities were analyzed in two dif-
ferent manners, including a separate analysis of samples
according to the clinical status of the sampled site (healthy,
erythematous, or ulcerated) and an analysis in which data
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from different sites within a subject were combined and
analyzed as one mucosal unit.
Evaluation of the antimicrobial activity of
chemotherapeutics
To evaluate the effect of antineoplastics on the whole cul-
tivable salivary microbiota, unstimulated saliva from eight
subjects was collected in sterile tubes. Aliquots were incu-
bated with 5-FU (7.7 μM), 5-FU (7.7 μM) + docetaxel
(1.2 μM), or a vehicle control, at 37 °C for 2 h. Samples
were serially diluted and plated on solid media containing
tryptic soy agar (20 g/L), brain heart infusion agar (26 g/
L), yeast extract (10 g/L), sheep blood (5% vol/vol), hemin
(5 μg/mL), menadione (0.3 μg/mL), and N-acetyl muramic
acid (10 ug/mL) for enumeration of salivary bacteria [59].
Sets of duplicate plates were incubated either anaerobic-
ally or aerobically at 37 °C for 5 days.
To evaluate the effect of 5-FU on pure bacterial cul-
tures, microorganisms were grown in appropriate
medium and atmosphere under late logarithmic phase
and this culture was diluted in fresh medium to an
OD(600 nm) = 0.4. Normalized culture aliquots were incu-
bated with different concentrations of 5-FU or with a ve-
hicle control for 2 h, at 37 °C, under an appropriate
atmosphere, after which cultures were serially diluted
and plated for colony forming unit determination. The
effect of 5-FU on the growth of S. salivarius ATCC 9222
and F. nucleatum ATCC 49256 was determined by add-
ing 5-FU or vehicle control to starter cultures diluted to
an OD = 0.1. Growth was followed until early stationary
phase. Inhibition was determined by comparing the area
under the curve of test conditions compared to control
vehicle. All experiments were repeated three times. Con-
centrations tested of 5-FU and docetaxel in the above
experiments were based on their bioavailability in
plasma and oral fluids [59, 60].
Changes in global oral epithelial gene expression during
chemotherapy
RNA was isolated from cytologic smears using the miR-
Neasy Mini Kit (Qiagen). RNA quantity and quality were
measured using the Experion High Sensitivity RNA Kit.
As previously observed by others [61], RNA quantity and
quality from oral epithelium varies with some samples
showing very low yields and high degradation. Therefore,
we employed the whole genome cDNA-mediated Anneal-
ing Selection Extension and Ligation assay (wgDASL) in
combination with the HumanHT-12 v4 Expression Bead
Chip (Illumina), to evaluate gene expression. This assay
performs well with partially degraded RNA as it does not
depend on an intact poly-A tail for cDNA synthesis [62].
Only subjects with matched baseline and V3 samples that
yielded at least 500 ng of RNA were included in the ana-
lysis. The wgDASL assay was performed with 250 ng of
RNA, including two technical replicates. Initial data ana-
lysis to eliminate samples that did not perform well in the
assay was carried out using GenomeStudio (Illumina).
Data were first normalized using the quantile method,
followed by filtering out probes without a detection p
value < 0.05 in at least one sample. Outlier samples for
which technical replicates did not have a correlation of at
least r = 0.95 were removed from the dataset. Differential
gene expression analysis in 14 subject-paired samples
from baseline to V3 was then performed using Signifi-
cance Analysis of Microarrays (SAM) [63]. Gene ontology
enrichment analysis was performed using DAVID [64],
and redundant GO terms summarized and visualized
using REVIGO [65].
Effect of commensals on a 3D oral mucosa analog tissue
To evaluate the response of the oral mucosa to microbial
commensals, 3D multi-layered epithelial cell constructs
derived from primary keratinocytes (EpiOral™, MatTek
Corporation) were challenged with 108 bacterial cells per
cm2. Microorganisms were placed apically and incubated
with tissues for 24 h. Membranes containing tissues were
harvested and used for histologic sectioning or RNA ex-
traction. Cell death was evaluated in tissue sections via
the DeadEnd™ Fluorometric TUNEL System (Promega).
RNA was extracted via Qiagen’s RNeasy mini kit, reverse
transcribed using the High Capacity RNA-to-cDNA Kit
(Applied Biosystems), and evaluated via real-time PCR
using TaqMan Assays (Applied Biosystems). The 18S
rRNA gene was used as endogenous control.
Statistical analyses
Baseline data were compared between groups by either
chi-square or Fisher’s exact test, the latter applied when
more than 20% of table cell counts had expected frequen-
cies < 5. Continuous data were evaluated via independent
sample t tests or Mann-Whitney U tests, according to
data distribution. The distribution of continuous data was
tested for normality using measures of Skewness and
Kurtosis and the Shapiro-Wilk test for normality in SPSS.
Differences in mucositis incidence across regimens were
evaluated via chi-square. Longitudinal data were evaluated
in subject-matched samples. Of interest was how changes
in one variable were associated with changes in another
variable or with one time-point measures. Specifically, we
were interested in the longitudinal analysis of changes in
mucositis scores and the relationship of these changes
with other variables. We therefore modelled the change in
each longitudinal variable using linear or quadratic
orthogonal polynomial contrasts. For this, each data point
was multiplied by a standard coefficient (for a linear or
quadratic 4 level contrast) and data aggregated by subject.
Correlations between linear or quadratic longitudinal
change and other variables were determined via Spearman
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Rank tests. Differences in clinical variables and micro-
biome diversity from baseline to each visit were calculated
using paired-Wilcoxon Rank tests. The change in alpha-
diversity (measured with the non-parametric Shannon
Index) was also evaluated by subtracting values at each
visit from the respective baseline values. Correlations be-
tween the difference in non-parametric Shannon Index
values and other variables were evaluated via Spearman
Rank tests. To quantify changes in community structure
during chemotherapy, we calculated the ThetaYC distance
of each sample to its corresponding baseline and com-
pared distances to control subjects via Mann-Whitney
Rank tests. ThetaYC distances were also evaluated for their
correlation with demographic and clinical variables via
Spearman Rank tests. Linear regression analysis was used
to evaluate the contribution of different predictors to
alpha- and beta-diversity microbiome change. Changes in
salivary community structure during chemotherapy and
correlation of these changes with clinical variables and
microbiome diversity were also visualized in Principal Co-
ordinates Analysis (PCoA) plots based on the ThetaYC
distances. Significant separation between data clouds was
tested via AMOVA and the correlations of principal com-
ponents with metadata were evaluated via Spearman Rank
tests. Differences in relative abundances of individual
microbial taxa from baseline to each visit were evaluated
via Wilcoxon signed rank tests. The significance threshold
for all statistical tests mentioned above was adjusted using
the Benjamini Hochberg false discovery rate method.
Evaluation of the longitudinal covariation in microbial
relative abundances and clinical parameters measured at
the four visits of the study was performed using the R
package MixOmics [66]. For this analysis, we used the
multilevel function and compared microbial and clinical
variables using sparse Partial Least Squares (sPLS). This
multilevel multivariate approach takes into account the re-
peated measures within subjects and by using sPLS reveals
covariation patterns in all variables in an unsupervised
manner. Differences in colony forming units (CFUs) re-
covered after treatment of saliva or pure bacterial cultures
with antineoplastics were determined via paired Wilcoxon
signed rank tests. Differences in growth of bacteria in the
presence and absence of 5-FU were determined by
comparing the area under the growth curve for different
conditions via t tests.
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